About this community
Undertakes innovative biomedical research to discover the molecular mechanisms that underlie normal cellular processes and functions, and how, over lifetime, their failure or abnormality may lead to disease
The Babraham Institute is located six miles south-east of the university city of Cambridge, UK. We undertake innovative biomedical research to discover the molecular mechanisms that underlie normal cellular processes and functions, and how, over lifetime, their failure or abnormality may lead to disease. The Institute is a registered charity, sponsored by the Biotechnology and Biological Sciences Research Council (BBSRC), to underpin its national responsibilities for healthcare research and training.
Our research is also supported by the Medical Research Council (MRC) and many medical charities and other organisations.
Sub-communities within this community
Collections in this community
Interrogating novel functions of the I kappa B kinases via CRISPR-Cas9 gene editing and small molecule inhibition (2018-10-20)The NF-kB signalling pathway is a critical mediator of the cellular responses to inflammatory cytokines. The IκB kinase (IKK) complex, which is composed of two catalytic subunits (IKKα and IKKβ) and one regulatory subunit ...
(2017-04-29)DNA methylation entails the addition of a methyl group to the 5-carbon of the cytosine base of the DNA. This modification is important during many biological processes such as imprinting, X-chromosome inactivation, cell ...
Control of Cardiac Remodelling during Ageing and Disease by Epigenetic Modifications and Modifiers (2018-07-21)The mammalian heart is a remarkable organ in that it must provide for the cardiovascular needs of the organism throughout life, without pausing. Yet, through developmental growth to adulthood and into ageing, the mammalian ...
(2018-07-05)DNA methylation is an important epigenetic mark spanning all of life's kingdoms. In humans, DNA methylation has been associated with a wide range of age-related pathologies, including type II diabetes and cancer. More ...